CN101073556A - Eyes preparation for divergent pupil and its making method - Google Patents
Eyes preparation for divergent pupil and its making method Download PDFInfo
- Publication number
- CN101073556A CN101073556A CNA200710024611XA CN200710024611A CN101073556A CN 101073556 A CN101073556 A CN 101073556A CN A200710024611X A CNA200710024611X A CN A200710024611XA CN 200710024611 A CN200710024611 A CN 200710024611A CN 101073556 A CN101073556 A CN 101073556A
- Authority
- CN
- China
- Prior art keywords
- ophthalmic preparation
- mydriasis
- mydriatic
- regulator
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 47
- 210000001508 eye Anatomy 0.000 title abstract description 13
- 238000000034 method Methods 0.000 title abstract 2
- 210000001747 pupil Anatomy 0.000 title 1
- 208000006550 Mydriasis Diseases 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229920001983 poloxamer Polymers 0.000 claims abstract description 16
- 229960000502 poloxamer Drugs 0.000 claims abstract description 14
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960001631 carbomer Drugs 0.000 claims abstract description 8
- 230000002421 anti-septic effect Effects 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 4
- 230000002911 mydriatic effect Effects 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 11
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 229960004791 tropicamide Drugs 0.000 claims description 10
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 claims description 9
- 229960002028 atropine sulfate Drugs 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 239000008215 water for injection Substances 0.000 claims description 7
- 229920002148 Gellan gum Polymers 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000000216 gellan gum Substances 0.000 claims description 6
- 235000010492 gellan gum Nutrition 0.000 claims description 6
- 239000012982 microporous membrane Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 229960003733 phenylephrine hydrochloride Drugs 0.000 claims description 4
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 229950008882 polysorbate Drugs 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 3
- 108010010803 Gelatin Proteins 0.000 abstract 1
- 239000011149 active material Substances 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 239000008273 gelatin Substances 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 235000011852 gelatine desserts Nutrition 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 230000005923 long-lasting effect Effects 0.000 abstract 1
- 230000001144 postural effect Effects 0.000 abstract 1
- 235000019633 pungent taste Nutrition 0.000 abstract 1
- 230000007704 transition Effects 0.000 abstract 1
- 239000003889 eye drop Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 5
- 229960000686 benzalkonium chloride Drugs 0.000 description 4
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 4
- 239000003885 eye ointment Substances 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 230000009969 flowable effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010022941 Iridocyclitis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 201000004612 anterior uveitis Diseases 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004083 nasolacrimal duct Anatomy 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N o-dicarboxybenzene Natural products OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
- 229940100655 ophthalmic gel Drugs 0.000 description 1
- -1 phthalic acid ester Chemical class 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008337 systemic blood flow Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 208000005494 xerophthalmia Diseases 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention is concerned with the method of preparation of the Mydriasis ophthalmic preparation. It is the kind of ophthalmic preparation that in liquid form before dripping into eyes but turns to gelatin postural after. It contents Mydriasis agent as the active material and other supplementary materials, such as poloxamer, carbomer, Deacetylcephalomannine Gellan Gum, transition regulator and medicinal acceptable antiseptic, isoosmotic adjustment, PH regulator and injection usage water. It can use of optometry, pre-operation naydriasis, etc. The advantages of the invention are: highly biocompatibility, low pungency, and long lasting.
Description
Technical field
The present invention relates to a kind of mydriasis ophthalmic preparation, especially external is thinlyfluid, and generation is transformed into mutually to be and solidifies or thick preparation and preparation method thereof in the body.
Background technology
Current clinical mydriatic commonly used occurs with conventional dosage forms such as eye drop, eye ointment mostly, eye drop is as the most frequently used topical dosage form of ophthalmology, after splashing into ophthalmic, can be diluted to 0.1% of original concentration by tear in several minutes, therefore need to increase the eye dripping frequency, use inconvenience, and the part eye drop enters the systemic blood circulation through nasolacrimal duct, easily cause untoward reaction.Though eye ointment can avoid eye drop easily to cause the defective of systemic adverse reactions, but its release is slow, need shift to an earlier date use in several days during optometry, bring very big trouble to life, and with vaseline as substrate, greasy feeling is strong, affects one's power of vision after the use and attractive in appearance, night, clothing was easily polluted in use again, so the patient not too is willing to use.This situation impels people to carry out the development work of gel preparation, for example the Chinese patent CN1189773A of Germany's lid Hartmann chemical pharmacy company limited application is a kind of aseptic dropped in eyes gel preparation, it has a kind of water and a kind of hydrophobic biphase carrier liquid or gel base material mutually of containing, material is mainly polyacrylic acid or polymeric acrylic acid derivative and derivative of fatty acid, triglyceride and/or phthalic acid ester, mainly be to solve under condition without emulsifying agent, obtain a kind of interpolation active substance and homodisperse gel, but it mainly is to be used for artificial tears and processing " xerophthalmia ", but not the treatment ocular infection.
Because gel for eye use adopts aqueous matrix, excellent biological compatibility is arranged, zest is little, it not only has some advantages of Eye ointments, as increasing the time of contact in medicine and affected part, the effect time limit of prolong drug, and can alleviate medicine to the friction of eyeball with overcome the problem of blurred vision.The gel for eye commodity are also arranged in the market, but mostly be thick semisolid, if directly gel drops is gone into ophthalmic, because of gel lacks good spreadability within the eye, medicine is difficult for being evenly distributed, using dosage can not accurately be controlled simultaneously, also may influence attractive in appearance and vision, thereby needs further to improve.
Summary of the invention
The purpose of this invention is to provide a kind of mydriasis ophthalmic preparation and preparation method thereof, said preparation is a kind of ophthalmic preparation that splashes into ophthalmic gel attitude in external one-tenth liquid condition, can be applicable to ophthalmology optometry inspection, the preceding mydriasis of ophthalmologic operation, postoperative prevents adhesion, also can be used for treatments such as keratitis, iridocyclitis.
For realizing purpose of the present invention, a kind of mydriasis ophthalmic preparation, form by following component:
Constituent content (weight %)
Mydriatic 0.01-5
Poloxamer 10-30
Carbomer 0-5
Remove acetyl-removed gellan gum 0-5
Change regulator 0-10 mutually
Other ophthalmic preparation adjuvant 0-10
The water for injection surplus.
Further, above-mentioned mydriasis ophthalmic preparation, wherein, described mydriatic is atropine sulfate (Atropine Sulfate), or tropicamide (Tropicamide), or the mixture of tropicamide and phenylephrine hydrochloride.
Further, above-mentioned mydriasis ophthalmic preparation, wherein, the described regulator that changes mutually is a polysorbate, or Polyethylene Glycol (PEG); Described other ophthalmic preparation adjuvant comprises antiseptic, isoosmotic adjusting agent, PH regulator.
Again further, above-mentioned mydriasis ophthalmic preparation, wherein, described mydriatic is an atropine sulfate, at this moment, the weight content of mydriatic is that the weight content of 0.5-2.0%, poloxamer is 10-30%.
The preparation method of mydriasis ophthalmic preparation of the present invention, be prepared according to the following steps: at first take by weighing each component according to the described consumption of claim 1, then mydriatic is dissolved in water, add poloxamer, carbomer again, go acetyl-removed gellan gum, change regulator and other ophthalmic preparation adjuvant mutually, stirring and dissolving, adjusting PH is 5-9, and solution is by filtering with microporous membrane, again in add water to total amount on filter.
Ophthalmic preparation of the present invention external be thinlyfluid, splashing into ophthalmic becomes viscous gel.Said preparation can be in following 2 seconds to 5 minutes at 25-37 ℃ and solidifies or thick; Be placed on again in the cold water, can revert to low-viscosity flowable liquids state again.Its toxicity is low, and zest is little, and good biocompatibility can improve patient's compliance and toleration.Compare with conventional dosage forms commonly used such as eye drop, eye ointment, mydriasis ophthalmic preparation provided by the invention has following advantage:
1. be liquid condition under this product room temperature, dosage is accurately control, easy to use easily, and be easy to sprawl after splashing into ophthalmic;
2. gel is an aqueous matrix, and viscosity is moderate, and lubricity is good, and to the eye nonirritant, and the transparency is good, does not influence sight line, and therefore trace stain not after the use can not influence attractive in appearancely, uses comfortable;
3. after gel drops was gone into ophthalmic, uniform spreading sticked to eyeball and eyelid surface and becomes gel, can major part not run off as eye drop, medicine can discharge rapidly from substrate, and keeps long relatively treatment time, more can bring into play therapeutical effect than eye drop, strengthen therapeutic effect;
4. ophthalmic preparation of the present invention is plasticity or pseudoplastic behavior on rheology, viscosity reduces with nictation, and use feeling is comfortable, when not batting an eyelid, can recover viscosity again;
5. but this product Entkeimung is compared with gel preparation, and production technology is more easy.
The specific embodiment
The present invention proposes a kind of mydriasis ophthalmic preparation, comprises following component:
Constituent content (weight %)
Mydriatic 0.01-5
Poloxamer 10-30
Carbomer 0-5
Remove acetyl-removed gellan gum 0-5
Change regulator 0-10 mutually
Other ophthalmic preparation adjuvant 0-10
The water for injection surplus.
In the above-mentioned prescription, mydriatic is the active component in the ophthalmic preparation of the present invention, and it is atropine sulfate (Atropine Sulfate), or tropicamide (Tropicamide), or the mixture of tropicamide and phenylephrine hydrochloride.Poloxamer (Poloxamer) is one or more the mixture among Poloxamer 407 (Lutrol F127) or the Poloxamer 188 (Lutrol F68).Change regulator mutually and can select polysorbate or Polyethylene Glycol (PEG) for use, perhaps do not add and change regulator mutually.Other ophthalmic preparation adjuvant is meant acceptable ophthalmic preparation additive on the pharmaceutics, comprises antiseptic, isoosmotic adjusting agent, PH regulator etc.
The physicochemical character of formulation products of the present invention is:
(1) external is thinlyfluid, and splashing into ophthalmic becomes viscous gel.
(2) said preparation can be in following 2 seconds to 5 minutes at 25-37 ℃ and solidifies or thick; Be placed on again in the cold water, can revert to low-viscosity flowable liquids state again.Particularly, said preparation can be in second at 30-34 ℃ of following 2-60 and solidifies or thick; Be placed on again in the cold water, can revert to low-viscosity flowable liquids state again.
(3) in 25-37 ℃ of scope, produce gelling, take place to change into mutually by thinlyfluid and solidify or thick.Particularly, in 30 ℃ of-34 ℃ of scopes, produce gelling, take place to change into mutually by thinlyfluid and solidify or thick.The said temperature scope can be regulated by changing regulator mutually.
Below in conjunction with specific embodiment technical solution of the present invention is described further.These examples only are some exemplary applications, can not be interpreted as a kind of restriction to claim protection domain of the present invention.
Embodiment 1
Get water for injection 39Kg, add atropine sulfate 0.5Kg, stir and make dissolving.Get poloxamer 9Kg, be sprinkled into above-mentioned solution, standing over night; Add benzalkonium chloride 0.005Kg, sodium chloride 0.4Kg again, and the 2.5Kg polysorbate20, stirring and dissolving is regulated PH.Solution adds water to total amount 50Kg by 0.22 μ m filtering with microporous membrane on filter.Quality Identification is carried out in sampling, and qualified back is sub-packed in eye drip with in the bottle under gnotobasis, and packing promptly.
Embodiment 2
Get water for injection 39Kg, add atropine sulfate 0.5Kg, stir and make dissolving.Get poloxamer 8Kg, carbomer 0.15Kg, Polyethylene Glycol (PEG4000) 0.5Kg are sprinkled into above-mentioned solution, and standing over night adds benzalkonium chloride 0.005Kg again, and stirring and dissolving is regulated PH.Solution adds water to total amount 50Kg by 0.22 μ m filtering with microporous membrane on filter.Quality Identification is carried out in sampling, and qualified back is sub-packed in eye drip with in the bottle under gnotobasis, and packing promptly.
Embodiment 3
Get water for injection 39Kg, add tropicamide 0.25Kg, stir and make dissolving.Get poloxamer 8Kg, carbomer 0.15Kg is sprinkled into above-mentioned solution, and standing over night adds benzalkonium chloride 0.005Kg again, and stirring and dissolving is regulated PH.Solution adds water to total amount 50Kg by 0.22 μ m filtering with microporous membrane on filter.Quality Identification is carried out in sampling, and qualified back is sub-packed in eye drip with in the bottle under gnotobasis, and packing promptly.
Embodiment 4
Get water for injection 39Kg, add tropicamide 0.25Kg, phenylephrine hydrochloride 0.25Kg stirs and makes dissolving.Get poloxamer 12Kg, go acetyl-removed gellan gum 0.1Kg to be sprinkled into above-mentioned solution, standing over night adds benzalkonium chloride 0.005Kg again, and stirring and dissolving is regulated PH.Solution adds water to total amount 50Kg by 0.22 μ m filtering with microporous membrane on filter.Quality Identification is carried out in sampling, and qualified back is sub-packed in eye drip with in the bottle under gnotobasis, and packing promptly.
Through clinical confirmation, ophthalmic preparation provided by the invention, zest is little, toxicity is low, the compatibility is good, has significant mydriasis effect.It can form gel within the eye, reduces drug wastage, and the comparable similar eye drop of the access times of medicine is few, has so both guaranteed to greatly facilitate the patient again by therapeutic effect.Therefore, the present invention is in the field of business to have good application prospects, can be applicable to ophthalmology optometry inspection, and mydriasis, postoperative prevent adhesion before the ophthalmologic operation, also can be used for treatments such as keratitis, iridocyclitis.
Claims (6)
1. mydriasis ophthalmic preparation is characterized in that being made up of following component:
Constituent content (weight %)
Mydriatic 0.01-5
Poloxamer 10-30
Carbomer 0-5
Remove acetyl-removed gellan gum 0-5
Change regulator 0-10 mutually
Other ophthalmic preparation adjuvant 0-10
The water for injection surplus.
2. a kind of mydriasis ophthalmic preparation according to claim 1, it is characterized in that: described mydriatic is an atropine sulfate, or tropicamide, or the mixture of tropicamide and phenylephrine hydrochloride.
3. a kind of mydriasis ophthalmic preparation according to claim 1 and 2 is characterized in that:
The described regulator that changes mutually is a polysorbate, or Polyethylene Glycol.
4. a kind of mydriasis ophthalmic preparation according to claim 1 and 2 is characterized in that:
Described other ophthalmic preparation adjuvant comprises antiseptic, isoosmotic adjusting agent, PH regulator.
5. a kind of mydriasis ophthalmic preparation according to claim 2, it is characterized in that: described mydriatic is an atropine sulfate, at this moment, the weight content of mydriatic is that the weight content of 0.5-2.0%, poloxamer is 10-30%.
6. the preparation method of the described a kind of mydriasis ophthalmic preparation of claim 1, it is characterized in that being prepared according to the following steps: at first take by weighing each component according to the described consumption of claim 1, then mydriatic is dissolved in water, add poloxamer, carbomer again, go acetyl-removed gellan gum, change regulator and other ophthalmic preparation adjuvant mutually, stirring and dissolving, adjusting PH is 5-9, and solution is by filtering with microporous membrane, again in add water to total amount on filter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200710024611XA CN101073556A (en) | 2007-06-25 | 2007-06-25 | Eyes preparation for divergent pupil and its making method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200710024611XA CN101073556A (en) | 2007-06-25 | 2007-06-25 | Eyes preparation for divergent pupil and its making method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101073556A true CN101073556A (en) | 2007-11-21 |
Family
ID=38974935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200710024611XA Pending CN101073556A (en) | 2007-06-25 | 2007-06-25 | Eyes preparation for divergent pupil and its making method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101073556A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103239390A (en) * | 2013-05-15 | 2013-08-14 | 中国人民解放军第三军医大学第二附属医院 | Tropicamide ophthalmic temperature-sensitive in-situ gel and preparation method thereof |
| JP2014512387A (en) * | 2011-04-22 | 2014-05-22 | アルコン リサーチ， リミテッド | Ophthalmic composition with a viscosity enhancing system having two different viscosity enhancing agents |
| WO2012145460A3 (en) * | 2011-04-22 | 2014-07-24 | Alcon Research, Ltd. | Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents |
| CN104055729A (en) * | 2013-03-22 | 2014-09-24 | 上海现代药物制剂工程研究中心有限公司 | Azithromycin eye drops and preparation method thereof |
| CN104341414A (en) * | 2014-11-11 | 2015-02-11 | 武汉武药制药有限公司 | Preparation method of anticholinergic agent atropine sulphate |
| CN105213418A (en) * | 2015-11-11 | 2016-01-06 | 中国人民解放军第四军医大学 | Preoperative compound eye drops of a kind of ophthalmology and preparation method thereof |
| CN111920795A (en) * | 2020-09-11 | 2020-11-13 | 马明 | Mydriasis agent and preparation method thereof |
| CN113939287A (en) * | 2019-05-02 | 2022-01-14 | 优尼特尔制药公司 | Composition based on gellan gum and phenylephrine, method of production and use as ophthalmic product |
| WO2022144798A1 (en) * | 2020-12-30 | 2022-07-07 | Sentiss Pharma Private Limited | Mydriatic and anti-muscarinic agent composition for ophthalmic use |
-
2007
- 2007-06-25 CN CNA200710024611XA patent/CN101073556A/en active Pending
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014525891A (en) * | 2011-04-22 | 2014-10-02 | アルコン リサーチ， リミテッド | Ophthalmic composition with a viscosity enhancing system having two different viscosity enhancing agents |
| JP2014512387A (en) * | 2011-04-22 | 2014-05-22 | アルコン リサーチ， リミテッド | Ophthalmic composition with a viscosity enhancing system having two different viscosity enhancing agents |
| WO2012145460A3 (en) * | 2011-04-22 | 2014-07-24 | Alcon Research, Ltd. | Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents |
| AU2012245538B2 (en) * | 2011-04-22 | 2017-06-15 | Alcon Research, Ltd. | Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents |
| CN104039307A (en) * | 2011-04-22 | 2014-09-10 | 爱尔康研究有限公司 | Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents |
| CN104055729A (en) * | 2013-03-22 | 2014-09-24 | 上海现代药物制剂工程研究中心有限公司 | Azithromycin eye drops and preparation method thereof |
| CN103239390B (en) * | 2013-05-15 | 2014-08-06 | 中国人民解放军第三军医大学第二附属医院 | Tropicamide ophthalmic temperature-sensitive in-situ gel and preparation method thereof |
| CN103239390A (en) * | 2013-05-15 | 2013-08-14 | 中国人民解放军第三军医大学第二附属医院 | Tropicamide ophthalmic temperature-sensitive in-situ gel and preparation method thereof |
| CN104341414A (en) * | 2014-11-11 | 2015-02-11 | 武汉武药制药有限公司 | Preparation method of anticholinergic agent atropine sulphate |
| CN104341414B (en) * | 2014-11-11 | 2016-04-20 | 武汉武药制药有限公司 | A kind of preparation method of anticholinergic drug Tropintran |
| CN105213418A (en) * | 2015-11-11 | 2016-01-06 | 中国人民解放军第四军医大学 | Preoperative compound eye drops of a kind of ophthalmology and preparation method thereof |
| CN105213418B (en) * | 2015-11-11 | 2019-01-22 | 中国人民解放军第四军医大学 | A kind of compound eye drops for preoperative ophthalmology and preparation method thereof |
| CN113939287A (en) * | 2019-05-02 | 2022-01-14 | 优尼特尔制药公司 | Composition based on gellan gum and phenylephrine, method of production and use as ophthalmic product |
| CN111920795A (en) * | 2020-09-11 | 2020-11-13 | 马明 | Mydriasis agent and preparation method thereof |
| WO2022144798A1 (en) * | 2020-12-30 | 2022-07-07 | Sentiss Pharma Private Limited | Mydriatic and anti-muscarinic agent composition for ophthalmic use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101073556A (en) | Eyes preparation for divergent pupil and its making method | |
| CN1112918C (en) | Ophthalmic composition with decreased viscosity | |
| DE69117509T2 (en) | REVERSIBLE GELLED COMPOSITIONS AND METHODS FOR USE | |
| US4255415A (en) | Polyvinyl alcohol ophthalmic gel | |
| CN101564374A (en) | Medicinal in situ forming eye gel | |
| CN109481450A (en) | A kind of eye-drops preparations and preparation method thereof for preventing and treating cataract | |
| CN1144476A (en) | Ophthalmic composition containing ion sensitive, hydrophilic polymer and inorganic salt in ratio which gives low viscosity | |
| EP1754491B1 (en) | Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist | |
| CN111803441A (en) | Sodium hyaluronate eye drops containing 0.01% atropine and preparation method thereof | |
| CN1089837A (en) | ophthalmic preparation | |
| CN101536974A (en) | Eye methazolamide temperature-sensitive situ-gel preparation and preparation method thereof | |
| CN1194664C (en) | In-vivo gel preparatino able to be dropped in eyes and its preparing process | |
| US20190192427A1 (en) | Azole compound ophthalmic preparation | |
| CN111494305A (en) | Lutein liposome ophthalmic temperature-sensitive in-situ gel preparation and preparation method thereof | |
| CN101278895A (en) | Instant type gel preparation for eye and method of producing the same | |
| WO2023052977A1 (en) | Compositions, methods and uses thereof | |
| CN107970205B (en) | Disulfiram instant gel eye drops and preparation and application thereof | |
| KR100775065B1 (en) | Long-lasting effect eye drop composition and preparation method thereof | |
| CN101181228A (en) | Homatropine hydrobromide in-situ gel preparation capable of eye drops and preparation method thereof | |
| CN1206987C (en) | Indomethacin liposome eye drops | |
| CN102018656A (en) | Eye gel containing latanoprost used as effective component and preparation method thereof | |
| EP2800573B1 (en) | Ophthalmic composition | |
| RU2402316C2 (en) | Pharmaceutical antiglaucoma composition | |
| CN100496502C (en) | Preparation method of capsule drop for protecting eye | |
| CA2835013C (en) | Eye drops for treatment of conjunctivochalasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |